Table 4.
Univariate analysis of overall survival (logrank test)
| Covariate | N (%) | Median overall survival (months) | P-value |
|---|---|---|---|
| Age (years) | |||
| ≤75 | 160 (88.4%) | 41.3 | 0.0099* |
| >75 | 21 (11.6%) | 17.0 | |
| Gender | |||
| Male | 86 (47.5%) | 40.7 | 0.5338 |
| Female | 95 (52.5%) | 31.7 | |
| Histological differentiation | |||
| Well/moderate | 151 (83.4%) | 42.5 | 0.5951 |
| Poorly/unknown | 30 (16.6%) | 25.3 | |
| Primary tumor | |||
| Colon | 67 (37.0%) | 24.5 | 0.0006* |
| Sigmoid/rectum | 114 (63.0%) | 45.7 | |
| Performance status (World Health Organization) | |||
| 0–1 | 171 (94.5%) | 41.0 | 0.0016* |
| 2 | 10 (5.5%) | 13.0 | |
| Performance status (Karnofsky) | |||
| ≤80 | 11 (6.1%) | 13.5 | 0.0048* |
| >80 | 170 (93.9%) | 40.0 | |
| Invasive extent | |||
| Tx–2 | 23 (12.7%) | 23.8 | 0.4304 |
| T3–4 | 158 (87.3%) | 39.4 | |
| Nodal status | |||
| Negative | 27 (14.9%) | 33.3 | 0.9566 |
| Positive | 154 (85.1%) | 38.5 | |
| Sites of metastases | |||
| Liver | 116 (64.1%) | 30.2 | 0.0274* |
| Other | 65 (35.9%) | 47.0 | |
| Number of organs involved | |||
| 1 | 69 (38.1%) | 32.8 | 0.2686 |
| ≥2 | 112 (61.9%) | 39.4 | |
| Pretreatment carcinoembryonic antigen level (ng/mL) | |||
| ≤5 | 101 (55.8%) | 24.5 | <0.0001* |
| >5 | 80 (44.2%) | 55.8 | |
| Proportion score | |||
| ≤3 | 144 (79.6%) | 40.4 | 0.0075* |
| >3 | 37 (20.4%) | 26.4 | |
| Intensity score | |||
| ≤1 | 114 (63.0%) | 40.5 | 0.8227 |
| >1 | 67 (37.0%) | 34.4 | |
| Total score | |||
| ≤4 | 130 (71,8%) | 39.7 | 0.0335* |
| >4 | 51 (28,2%) | 27.2 | |
Note:
*
Statistically significant (P < 0.05).